# US 2013/0281386 A1 · Glufosfamide Combination Therapies for Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0281386 A1
- Document ID: US20130281386A1
- Status: Published application
- Kind: A1
- Application number: 13/599,684
- Filed: 2012-08-30
- Published: 2013-10-24
- Earliest claimed: 2012-04-19
- Assignees: Eleison Pharmaceuticals LLC
- Inventors: Forrest H. Anthony; Edwin J. Thomas; Matthew Parris
- Web page: https://patentgrep.com/patent/US20130281386A1

## CPC

- A61K 31/7024: Esters of saccharides
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compositions and methods for treating cancer with glufosfamide in combination with an inhibitor of sodium-glucose transporter type 2 (SGLT2) to block the uptake of glucose in the proximal tubules of the kidneys to decrease renal toxicity. The invention relates to the fields of biomedicine, pharmacology, and molecular biology.

## Claims

### Claim 1

A combination therapy comprising:
(i) an inhibitor of a kidney glucose transporter protein
(ii) an effective amount of a glucose-conjugated chemotherapeutic drug such as glufosfamide.

### Claim 2 (depends on 1)

The therapy of claim 1, wherein said kidney glucose transporter inhibitor is an SGLT2 inhibiting drug.

### Claim 3 (depends on 2)

The therapy of claim 2, wherein said SGLT2 inhibitor is selected from the group consisting of dapagliflozin, canagliflozin, ipragliflozin, tofogliflozin, BI-10773, sergliflozin etabonate, remogliflozin etabonate, and combinations thereof.

### Claim 4 (depends on 2)

The therapy of claim 2, wherein said sodium glucose transporter type 2 inhibitor is dapaglifozin.

### Claim 5 (depends on 1)

The therapy of claim 1, wherein said chemotherapeutic drug is selected from the group consisting of: any cytotoxic, cytostatic agent, or molecularly targeted anticancer agent conjugated with glucose.

### Claim 6 (depends on 1)

The therapy of claim 1, wherein said chemotherapeutic drug is glufosfamide.

### Claim 7

A method of treating cancer in a patient comprising administering a therapeutically effective amount of glufosfamide in combination with sodium-glucose transporter type 2 inhibitor to a patient in need of a cancer treatment.

### Claim 8 (depends on 7)

The method of claim 7, wherein said cancer is pancreatic adenocarcinoma.

### Claim 9 (depends on 7)

The method of claim 7, wherein said sodium-glucose transporter type 2 inhibitor is selected from the group consisting of dapagliflozin, canagliflozin, ipragliflozin, tofogliflozin, BI-10773, sergliflozin etabonate, remogliflozin etabonate, and combinations thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein said sodium-glucose transporter type 2 inhibitor is dapagliflozin.

### Claim 12

A method of treating a patient diagnosed with cancer, said method comprising the steps of:
(i) administering an agent that inhibits the absorption of glucose by the kidneys to said patient; and
(ii) administering a therapeutically effective amount of glucose-conjugated chemotherapeutic agent to said patient.
